购物车0
产品总数：56323
| 中文名称 |
硝苯吡啶.
|
|---|---|
| 中文别名 |
硝苯地平;1,4-二氢-2,6-二甲基-4-(2-硝基苯基)-3,5-吡啶二羧酸二甲酯;心痛定;利心平;硝苯吡啶;硝苯啶;硝基地平;硝苯地平(心痛定);硝苯地平 GMP;Nifedipine 硝苯地平;长效冠脉扩张药硝苯地平;磷酸肌酸钠;硝苯地平 EP标准品;硝苯地平 USP标准品;硝苯地平 标准品;硝苯地平-D6;硝苯地平长效冠脉扩张药;硝苯地平欢迎来电洽谈;硝苯地平杂质
|
| 英文名称 |
Nifedipine
|
| 英文别名 |
Nifedipine;1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylicaciddime;3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester;4-(2’-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethy;5-pyridinedicarboxylicacid,1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-dim;Adalat CC;bay1040;corinfar;Dimethyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate;ALDIPIN ANIFED;Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate;dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;nifedipin;Nifedipine (BAY 1040, Cordipin, Adalat®, Nifediac®, Nifedical®, Procardia®, Afeditab® );1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic Acid Dimethyl Ester;4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridine;Adalat;Cordipin;Fenihidin;Fenihidine;Procardia;Procardia XL;Dimethyl 1,4-dihydro-2,6-dimethyl-4-(2'-nitrophenyl)-3,5-pyridinedicarboxylate;Oxcord;Citilat;Adalate;Nifediac;Afeditab CR;Hexadilat;Tibricol;Nifangin;Kordafen;Nifedical;Introcar;Coracten;Pidilat;Zenusin;Adapine;Sepamit;Anifed;Orix;Adalat LA;Nifedipinum;Dignokonstant;Chronadalate;Nifelat;Nifedin;Nifedicor;Nifecard;Megalat;Macorel;Fenamon;Corotrend;Cordicant;Cordafen;Nifedipino;Ecodipin
|
| Cas No. |
21829-25-4
|
| 分子式 |
C17H18N2O6
|
| 分子量 |
346.33
|
| 包装储存 |
4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| 生物活性 |
Nifedipine (BAY-a-1040) is a potent calcium channel blocker and drug of choice for cardiac insufficiencies. |
|---|---|
| 性状 |
Solid |
| 体外研究(In Vitro) |
Nifedipine (BAY-a-1040) (100 μM) significantly lowers the viability of the WKPT-0293 Cl.2 Cells, and treatment of nifedipine (10 or 100 μM) plus FAC induces a significant reduction in cell viability, but there are no significant differences in viability between the control cells and the cells treated with 100 μM of FAC or 1 and 10 μM of nifedipine.Nifedipine (BAY-a-1040) (1, 10, or 100 μM) significantly increases iron level in WKPT-0293 Cl.2 cells. Nifedipine treatment also increases expression of TfR1, DMT1+IRE and DMT1-IRE in WKPT-0293 Cl.2 cells. In addition, co-treatment with nifedipine (100 μM) and FAC (100 μM) increases TfR1, DMT1+IRE and DMT1-IRE expression in WKPT-0293 Cl.2 cells. Nifedipine plus ritodrine produces a significantly greater inhibition of contractility than each drug alone in the midrange of concentrations. The combination of nifedipine plus nitroglycerin or nifedipine plus atosiban produces a significantly greater inhibition than nitroglycerin or atosiban alone but not greater than nifedipine. The combination of nifedipine plus NS-1619 (Ca-activated K [BKCa] channel opener) reduces the inhibitory effect of each drug. Nifedipine (BAY-a-1040) (2 μM) significantly inhibits P. capsici mycelial growth and sporulation. Nifedipine (BAY-a-1040)-induced inhibition of mycelial growth is calcium-dependent. Nifedipine (0.5 μM) increases P. capsici sensitivity to H2O2 in a calcium-dependent manner. Nifedipine inhibition of P. capsici virulence and expression of genes involved in pathogenicity. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
| 体内研究(In Vivo) |
In Nifedipine (BAY-a-1040) (50 mg/kg)- and CsA-treated rats, the BL dimensions (BLi and BLk), MD dimensions (MDk) and vertical dimensions (VHi and VHk) are significantly increased (P < 0.05) at the end of the 4th week. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
| 运输条件 |
Room temperature or refrigerated transportation. |
| 储存方式 |
4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| ClinicalTrial |
|
| 参考文献 |
|
| 溶解度数据 |
体外研究:
DMSO : 100 mg/mL (288.74 mM; Need ultrasonic) H2O : 1 mg/mL (2.89 mM; ultrasonic and warming and heat to 80°C) 配制储备溶液
*
产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。 体内研究:
建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
*
|
|---|
[1]. Ratre MS, et al. Effect of azithromycin on gingival overgrowth induced by cyclosporine A + nifedipine combination therapy: A morphometric analysis in rats. J Indian Soc Periodontol. 2016 Jul-Aug;20(4):396-401. [Information]
[2]. Carvajal JA, et al. The Synergic 体外研究 Tocolytic Effect of Nifedipine Plus Ritodrine on Human Myometrial Contractility. Reprod Sci. 2017 Apr;24(4):635-640. [Information]
[3]. Yu SS, et al. Nifedipine Increases Iron Content in WKPT-0293 Cl.2 Cells via Up-Regulating Iron Influx Proteins. Front Pharmacol. 2017 Feb 13;8:60 [Information]
[4]. Liu P, et al. The L-type Ca(2+) Channel Blocker Nifedipine Inhibits Mycelial Growth, Sporulation, and Virulence of Phytophthora capsici. Front Microbiol. 2016 Aug 4;7:1236. [Information]
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
